Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL)
- 3 August 2001
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 37 (2) , 97-102
- https://doi.org/10.1002/mpo.1176
Abstract
Background: Between 1976 and 1998, CD30+anaplastic large cell lymphoma (ALCL) was diagnosed in 44 children (28 males, 16 females, age range 2.7–16.1 years, median 10). Up to 1993, 32 such children were treated according to a common chemotherapeutic protocol that stratified patients according to stage, without considering presenting features. Thereafter, patients presenting with visceral (lung, spleen, liver, gastro‐intestinal tract) or mediastinal involvement were assigned to a high‐risk treatment protocol with induction intensification. The generation of these two risk‐groups was the result of a retrospective analysis of clinical risk factors for therapy failure as previously reported [Massimino M, Gasparini M, Giardini R, Ann Oncol 1995;6:915–920]. Considering the whole cohort of patients divided into group A—21/22 evaluable patients with visceral/mediastinal involvement, and group B—22 evaluable patients, with other ALCL location—disease‐free survival (DFS) and survival (S) at 5 years were 57 and 58% for group A, and 83 and 100% (94% at 6 years) for group B, respectively.Procedure: We tested 15/21 cases of group A, and 18/22 of group B for p80 immunoreactivity in order to investigate a possible correlation between ALCL locations and NPM‐ALK expression.Results: Thirteen of 15 specimens in group A and 17/18 in group B were positive for p80.Conclusions: It is impossible to conclude anything about p80 positivity based on a series of 33/44 patients with childhood ALCL, neither about over‐all prognosis nor about the role of visceral involvement. In adults, NPM‐ALK protein expression is a favourable prognostic factor. Med Pediatr Oncol 2001;37:97–102.Keywords
This publication has 22 references indexed in Scilit:
- ALK Expression Defines a Distinct Group of T/Null Lymphomas (“ALK Lymphomas”) with a Wide Morphological SpectrumThe American Journal of Pathology, 1998
- The t(2;5) in Human LymphomasLeukemia & Lymphoma, 1998
- Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1Blood, 1997
- Ki-l (CD30) anaplastic large-cell lymphoma in childrenAnnals of Oncology, 1995
- CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapyBlood, 1995
- Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1994
- Pediatric lymphomas: Recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhoodAnnals of Oncology, 1994
- CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35British Journal of Haematology, 1990
- Poor-risk non-lymphoblastic lymphoma of childhood: Results of an intensive pilot studyMedical and Pediatric Oncology, 1989
- A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki‐1 lymphoma')British Journal of Haematology, 1989